Prostate Cancer
Prostate cancer develops in the prostate gland, but its behaviour varies widely. A raised PSA is not a diagnosis; imaging and biopsy findings may be needed to establish whether cancer is present and how it should be managed.
Abiraterone Tablets
250mg
Abiraterone 250mg tablets, used in the management of prostate cancer. A CYP17A1 inhibitor that blocks androgen synthesis in the adrenal glands.
Key points
- Early prostate cancer may cause no symptoms, while advanced disease can cause urinary problems, bone pain, weakness or weight loss.
- Treatment decisions depend on stage, grade, PSA pattern, symptoms, life expectancy, other conditions and personal priorities.
- Options may include monitoring, surgery, radiotherapy or systemic treatment; catalogue medicines apply only within a specialist plan.
Catalogue matches do not diagnose prostate cancer or define a regimen; treatment requires urology or oncology assessment.
Why can treatment plans differ so much?
Some localised cancers are unlikely to cause harm and can be monitored. Higher-risk or spreading disease may need active treatment. Pathology and imaging help balance cancer control against urinary, sexual and other adverse effects.
What is the role of hormone treatment?
Many prostate cancers use androgen signalling. Medicines such as abiraterone or flutamide affect that pathway, but their place depends on disease setting, other medicines and monitoring needs. See oncology support for related entries.
When to seek urgent care
Seek urgent care for new leg weakness or numbness, loss of bladder or bowel control, inability to pass urine, severe new back pain, confusion or sudden worsening illness.